282 related articles for article (PubMed ID: 9761116)
1. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets.
Khyatti M; Stefanescu I; Blagdon M; Menezes J
J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983
[TBL] [Abstract][Full Text] [Related]
3. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
4. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
5. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
6. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
Yao QY; Rowe M; Morgan AJ; Sam CK; Prasad U; Dang H; Zeng Y; Rickinson AB
Int J Cancer; 1991 Apr; 48(1):45-50. PubMed ID: 1850382
[TBL] [Abstract][Full Text] [Related]
7. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
Shimakage M; Dezawa T; Chatani M
Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to LMP2A/2B in EBV-carrying malignancies.
Lennette ET; Winberg G; Yadav M; Enblad G; Klein G
Eur J Cancer; 1995 Oct; 31A(11):1875-8. PubMed ID: 8541116
[TBL] [Abstract][Full Text] [Related]
10. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma.
Ho HC; Ng MH; Kwan HC; Chau JC
Br J Cancer; 1976 Dec; 34(6):655-60. PubMed ID: 188437
[TBL] [Abstract][Full Text] [Related]
12. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
13. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk.
Coghill AE; Bu W; Hsu WL; Nguyen H; Yu KJ; Chien YC; Chen CJ; Cohen JI; Hildesheim A
J Infect Dis; 2018 Aug; 218(6):886-891. PubMed ID: 29718378
[TBL] [Abstract][Full Text] [Related]
15. An enzyme-linked immunosorbent assay for the measurement of human IgA antibody responses to Epstein-Barr virus membrane antigen.
Durda PJ; Sullivan M; Kieff E; Pearson GR; Rabin H
Intervirology; 1993; 36(1):11-9. PubMed ID: 8225907
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic importance of heterophile antibodies and immunoglobulins IgA, IgE, IgM and low-avidity IgG against Epstein-Barr virus capsid antigen in children.
Votava M; Bartosová D; Krchnáková A; Crhová K; Kubinová L
Acta Virol; 1996 Apr; 40(2):99-101. PubMed ID: 8886119
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology.
Gu AD; Xie YB; Mo HY; Jia WH; Li MY; Li M; Chen LZ; Feng QS; Liu Q; Qian CN; Zeng YX
J Gen Virol; 2008 May; 89(Pt 5):1152-1158. PubMed ID: 18420792
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response in Epstein-Barr virus infections. I. Elevated serum concentration of the IgG1 subclass in infectious mononucleosis and nasopharyngeal carcinoma.
Kaschka WP; Hilgers R; Skvaril F
Clin Exp Immunol; 1982 Jul; 49(1):149-56. PubMed ID: 6290114
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
[TBL] [Abstract][Full Text] [Related]
20. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
